Movement Disorders

Can we see changes in the brain that correspond to cognitive difficulties? Research presented at AAN 2016 offers compelling information.

January news includes the first FDA-approved drug for spinal muscular atrophy, various epilepsy treatments & vitamin D’s impact on Alzheimer & headache.

Orthostatic hypotension’s effect on cognition in Parkinson disease, testing patients with epilepsy who can drive safely, and carotid web are covered.

From Alzheimer disease to Zika virus, we’ve compiled a list of this year’s most popular articles on Neurology Times.

Ground-breaking research suggests that the gut microbiome may play a role in the pathogenesis of Parkinson disease.

November news includes the first human clinical trial focusing on tau in Alzheimer disease and Zika-related microcephaly not presenting at birth.

November news includes potential Alzheimer treatments, FDA approval of a device to prevent recurrent stroke, & a newly typified headache disorder.

Data blitz presentations at ANA 2016 featured studies on neuronal dysfunction and degeneration in ALS, Parkinson disease, transverse myelitis, & more.

Oct. news includes an approved deep brain stimulation system for movement disorders & biomarkers that improve risk assessment in atrial fibrillation.

Our Sept. news includes a possible clinical marker and therapy target in Alzheimer disease and MS findings from an optical coherence tomography study.

Our August news includes a potential classification system for Alzheimer disease, new findings in a 3D model of TBI, and migraine treatments.

A study of 30 years indicates the projected increase in Parkinson disease could be underestimated and offers possible explanations.

Recent neurological studies outline a link between TBI and Parkinson disease, discuss neuroimaging to predict recovery, and warn against DIY tDCS.

Our July news includes the Alzheimer-diabetes link, increased rates of Parkinson, and guidelines for acute migraine treatment in the ED.

Nuplazid, which the FDA designated as a breakthrough therapy and granted priority review, could help approximately 50% of Parkinson patients.

Our May news includes memory replay disruption in Alzheimer disease, impulse control disorder in Parkinson disease, and return to play in TBI.

Technology that is efficient yet lacking side effects, personalized, and nonintrusive may be closer than we think for many of our neurology patients.

Researchers gather environmental data to better understand possible mechanisms of Parkinson disease development.

Our Feb. news & research include two new migraine drugs, the stroke-Parkinson link, and the potential of an anticancer drug to prevent Alzheimer.

Our Jan. news & research list includes the possible lingering effects of childhood concussion and the benefits of vitamin D for MS.

Compliance, an obstacle in depression treatment for all patients, can be especially difficult for patients with dementia.

Our Dec. news & research list includes groundbreaking research from AES 2015 as well as a few potential neurodegeneration biomarkers.

A groundbreaking discovery may lead to repair of neurodegenerative diseases such as Alzheimer and Parkinson.

The holidays can be an especially stressful time of year, so patients need to be aware of how stress influences neurological disease progression.

The discovery of a possible trigger for PD and Lewy body dementia could provide a new avenue for gene therapy in these neurological conditions.